News

Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.

Global Media Contact
Almut Windhager, Ph.D.
press@rm.minaris.de

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.

June 4, 2019

apceth Will Operate as the Commercial Manufacturer in Europe for Zynteglo, bluebird bio’s Gene Therapy for β-thalassemia

Munich, Germany, June 4, 2019 - apceth Biopharma GmbH, a leading company for the manufacturing of cell and gene therapeutics, will operate as the commercial manufacturer in Europe for ZyntegloTM, a product of bluebird bio. Yesterday the European Commission (EC) has granted conditional marketing authorisation for ZyntegloTM, a gene therapy for patients 12 years and older with transfusion-dependent ...

All Posts

apceth Will Operate as the Commercial Manufacturer in Europe for Zynteglo, bluebird bio’s Gene Therapy for β-thalassemia

Subscribe to Our Email Distribution List